We previously revealed that the overexpression of synovial
aquaporin 1 (AQP1) aggravated
collagen-induced arthritis (CIA) in rats via regulating β-
catenin signaling. This study was to demonstrate the
therapeutic effect of
acetazolamide (AZ, an AQP1 inhibitor) on rat CIA and explored its underlying mechanisms. Paw swelling,
arthritis index, pathological assessments, and serum levels of
collagen type II (Col II) antibody, IL-1β and TNF-α were measured to evaluate the anti-arthritic effect of AZ on rat CIA. Ki67 immunohistochemistry and TUNEL assay were performed to reveal the anti-proliferative and pro-apoptotic effects of AZ on synovial cells in vivo. The
protein levels of apoptosis-related genes and Wnt/β-
catenin pathway key members were detected by western blot. We found that AZ treatment on CIA rats could inhibit paw swelling, reduce
arthritis index, alleviate the pathologic changes of ankle joint and decrease the serum levels of Col II antibody, TNF-α and IL-1β. AZ could reduce Ki67 expression and increase apoptosis index in CIA synovial tissues by reducing Bcl-2
protein level, increasing Bax and
caspase 3 protein levels and normalizing Bcl-2/Bax ratio. Moreover, AZ could reduce the
protein levels of Wnt1, β-
catenin, p-GSK-3β (Ser9), c-myc,
cyclin D1 and MMP9, while increase GSK-3β
protein level in CIA synovial tissues. Importantly, these mentioned effects of AZ (60 mg/kg) on CIA rats could be reversed by the combined use of
lithium chloride (LiCl), an activator of Wnt/β-
catenin pathway. In short, AZ exerted potent anti-arthritic effects on CIA rats by inducing synovial apoptosis and inhibiting Wnt/β-
catenin pathway.